EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy

Prachi Bhave iD, Angela Hong, Serigne N Lo iD, Rebecca Johnson, Johanna Mangana, Douglas B Johnson, Ozgecan Dulgar, Zeynep Eroglu iD, Hui-Ling Yeoh, Andrew Haydon, Georg C Lodde, Elisabeth Livingstone und 8 weitere

Journal for ImmunoTherapy of Cancer · 2023

DOI: 10.1136/jitc-2022-006629 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Prachi Bhave und 19 weiteren Autor:innen. Beteiligte Einrichtung: Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia. Hauptthemen laut MEDLINE: Quality of Life, Melanoma. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In patients with stage III melanoma, despite surgical resection and adjuvant systemic therapy, locoregional recurrences still occur. The randomized, phase III Trans-Tasman Radiation Oncology Group (TROG) 02.01 trial demonstrated that adjuvant radiotherapy (RT) after complete lymphadenectomy (CLND) halves the incidence of melanoma recurrence within local nodal basins without improving overall survival or quality of life. However, the study was conducted prior to the current era of adjuvant systemic therapies and when CLND was the standard approach for microscopic nodal disease. As such, there is currently no data on the role of adjuvant RT in patients with melanoma who recur during or after adjuvant immunotherapy, including those that may or may not have undergone prior CLND. In this study, we aimed to answer this question.

Methods

Patients with resected stage III melanoma who received adjuvant anti-programmed cell death protein-1 (PD-1) (±ipilimumab) immunotherapy with a subsequent locoregional (lymph node and/or in-transit metastases) recurrence were retrospectively identified. Multivariable logistic and Cox regression analyses were conducted. Primary outcome was rate of subsequent locoregional recurrence; secondary outcomes were locoregional recurrence-free survival (lr-RFS2) and overall RFS (RFS2) to second recurrence.

Results

In total, 71 patients were identified: 42 (59%) men, 30 (42%) BRAF V600E mutant, 43 (61%) stage IIIC at diagnosis. Median time to first recurrence was 7 months (1–44), 24 (34%) received adjuvant RT and 47 (66%) did not. Thirty-three patients (46%) developed a second recurrence at a median of 5 months (1–22). The rate of locoregional relapse at second recurrence was lower in those who received adjuvant RT (8%, 2/24) compared with those who did not (36%, 17/47, p=0.01). Adjuvant RT at first recurrence was associated with an improved lr-RFS2 (HR 0.16, p=0.015), with a trend towards an improved RFS2 (HR 0.54, p = 0.072) and no effect on risk of distant recurrence or overall survival.

Conclusion

This is the first study to investigate the role of adjuvant RT in patients with melanoma with locoregional disease recurrence during or after adjuvant anti-PD-1-based immunotherapy. Adjuvant RT was associated with improved lr-RFS2, but not risk of distant recurrence, demonstrating a likely benefit in locoregional disease control in the modern era. Further prospective studies are required to validate these results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeMelanomaMaleHumansFemaleRadiotherapy, AdjuvantRetrospective StudiesNeoplasm Recurrence, LocalAdjuvants, ImmunologicImmunotherapyCutaneous Malignant Melanoma

Stichwörter der Autor:innen

adjuvants, immunologicimmune checkpoint inhibitorsimmunotherapymelanomaradiotherapy

Substanzen

Adjuvants, Immunologic

Autor:innen und Institutionen

  • Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia.
  • Sir Peter MacCallum Cancer Centre Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
  • Melanoma Institute Australia, Sydney, New South Wales, Australia.
  • Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Department of Dermatology, University Hospital Zürich, Zurich, Switzerland.
  • Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

ORCID-Profile: Prachi Bhave, Serigne N Lo, Zeynep Eroglu

Zitieren

APA

Bhave, P., Hong, A., Lo, S. N., Johnson, R., Mangana, J., Johnson, D. B., Dulgar, O., Eroglu, Z., Yeoh, H. L., Haydon, A., Lodde, G. C., Livingstone, E., Khattak, A., Kähler, K., Hausschild, A., McArthur, G. A., Menzies, A. M., Long, G., Wang, W., & Carlino, M. S. (2023). Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2022-006629

Vancouver

Bhave P, Hong A, Lo SN, Johnson R, Mangana J, Johnson DB, et al. Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2022-006629

BibTeX
@article{Bhave2023,
  author = {Bhave, Prachi and Hong, Angela and Lo, Serigne N and Johnson, Rebecca and Mangana, Johanna and Johnson, Douglas B and Dulgar, Ozgecan and Eroglu, Zeynep and Yeoh, Hui-Ling and Haydon, Andrew and Lodde, Georg C and Livingstone, Elisabeth and Khattak, Adnan and Kähler, Katharina and Hausschild, Axel and McArthur, Grant A and Menzies, Alexander Maxwell and Long, Georgina and Wang, Wei and Carlino, Matteo S},
  title = {Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  doi = {10.1136/jitc-2022-006629}
}
Kostenlos starten →